國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Renal pharmacotherapydosage adjustme...

Golightly, Larry K.

Renal pharmacotherapydosage adjustment of medications eliminated by the kidneys /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Renal pharmacotherapyby Larry K. Golightly ... [et al.].
其他題名:	dosage adjustment of medications eliminated by the kidneys /
其他作者:	Golightly, Larry K.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	xxvi, 827 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Renal pharmacology.
電子資源:	https://doi.org/10.1007/978-3-030-58650-8
ISBN:	9783030586508$q(electronic bk.)

Renal pharmacotherapydosage adjustment of medications eliminated by the kidneys /
Renal pharmacotherapydosage adjustment of medications eliminated by the kidneys /[electronic resource] :by Larry K. Golightly ... [et al.]. - Second edition. - Cham :Springer International Publishing :2021. - xxvi, 827 p. :ill., digital ;24 cm.

A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.

ISBN: 9783030586508$q(electronic bk.)

Standard No.: 10.1007/978-3-030-58650-8doiSubjects--Topical Terms:

306373
Renal pharmacology.

LC Class. No.: RM145

Dewey Class. No.: 615.19

Renal pharmacotherapydosage adjustment of medications eliminated by the kidneys /
LDR:02743nmm a2200337 a 4500 001 609676
003 DE-He213
005 20210924160542.0
006 m d
007 cr nn 008maaau
008 220222s2021 sz s 0 eng d
020 $a 9783030586508$q(electronic bk.)
020 $a 9783030586492$q(paper)
024 7 $a 10.1007/978-3-030-58650-8 $2 doi
035 $a 978-3-030-58650-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RM145
072 7 $a MJR $2 bicssc
072 7 $a MED055000 $2 bisacsh
072 7 $a MJR $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM145 $b .R393 2021
245 0 0 $a Renal pharmacotherapy $h [electronic resource] : $b dosage adjustment of medications eliminated by the kidneys / $c by Larry K. Golightly ... [et al.].
250 $a Second edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xxvi, 827 p. : $b ill., digital ; $c 24 cm.
505 0 $a A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
520 $a To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
650 0 $a Renal pharmacology. $3 306373
650 0 $a Drugs $x Dosage. $3 302990
650 0 $a Drugs $x Metabolism. $3 194562
650 1 4 $a Nephrology. $3 274884
650 2 4 $a Pharmacology/Toxicology. $3 273652
650 2 4 $a Internal Medicine. $3 273839
650 2 4 $a Pharmacotherapy. $3 615025
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Drug Resistance. $3 338425
700 1 $a Golightly, Larry K. $3 907385
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-58650-8
950 $a Medicine (SpringerNature-11650)